Fresenius Kabi Oncology: Updates on delisting offer

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

DSP Merrill Lynch Ltd ("Manager to the Delisting Offer") on behalf of Fresenius Kabi (Singapore) Pte Ltd (“Acquirer”) has informed this Exit Offer Public Announcement ("Exit Offer PA") to the Equity Shareholders of the Fresenius Kabi Oncology Limited (“Company”). This Exit Offer PA provide the public shareholders of the Company an exit opportunity in accordance with Regulation 21 of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (“Delisting Regulations”). This Exit Offer PA is in continuation of and should be read in conjunction with the public announcement dated September 16, 2013 (“Public Announcement”) and letter of offer dated September 14, 2013 (“Letter of Offer”), as amended by the first corrigendum to the Public Announcement and the Letter of Offer published on October 13, 2013, the second corrigendum to the Public Announcement and the Letter of Offer published on October 19, 2013, the supplement to the second corrigendum (to the Public Announcement and the Letter of Offer) published on October 22, 2013 and the public announcement on success of the delisting offer dated October 30, 2013 (“Post Offer PA”).Capitalised terms used but not defined in this Exit Offer PA shall have the same meaning assigned to them as in the Public Announcement and the Letter of Offer.Source : BSE

Read all announcements in Fresenius Kabi

Read More